Acme Pharmaceuticals Announces That Phase III Trial of Compound X for Advanced Liver Cancer Met Primary Endpoint

Los Angeles, Calif.—Acme Pharmaceuticals (NYSE: ACM) announced today that its Phase III clinical trial of Compound X met its primary endpoint of improved overall survival for patients with advanced liver cancer, when compared with patients receiving a placebo. Full data has been submitted to the American Society of Clinical Oncology 2008 Annual Meeting.

“Acme is pleased to report that Compound X has shown significant results in the treatment of this historically hard-to-treat cancer,” said John Jones, MD, Acme’s chief executive officer. “We are deeply appreciative of the cancer patients and clinical investigators who participated in this important trial.”

An estimated 19,160 adults in the United States—13,650 men and 5,510 women—will be diagnosed with liver cancer in 2007, and an estimated 16,780 people—11,280 men and 5,500 women—will die from the disease this year. Liver cancer is the sixth most common cause of cancer death among men. The five-year relative survival rate of patients with liver cancer is 10.5 percent.

About the Compound X Trial
In this multi-national, Phase III, randomized, placebo-controlled trial, more than 300 patients with advanced hepatocellular carcinoma (HCC) who had no prior therapy were randomized to receive either Compound X or a placebo. The trial’s objective was to determine improved overall survival between the Compound X and placebo arms. Side effects were also studied; there were no significant differences in the side effects profile between the treatment and placebo arms.

About Acme Pharmaceuticals
[company boilerplate]

Forward Looking Statements
[company boilerplate]